Preferencje help
Polish version English version Język
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 17

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

Wyszukiwano:
w słowach kluczowych:  fibrinolytic agent
help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
1
Content available remote

Effects of direct oral anticoagulants on thromboelastographic parameters and fibrin clot properties in patients with venous thromboembolism

100%
Kopytek M., Zabczyk M., Natorska J., Malinowski K. P., Undas A.
Journal of Physiology and Pharmacology
|
2020
|
tom 71
|
nr 1
2
Content available remote

Multicenter analysis of EndoClot as hemostatic powder in different endoscopic settings of the upper gastrointestinal tract

86%
Hagel A. F., Raithel M., Hempen P., Preclik G., Dauth W., Neurath M. F., Gschossmann J., Konturek P. C., Albrecht H.
Journal of Physiology and Pharmacology
|
2020
|
tom 71
|
nr 5
3
Content available remote

Pharmacogenetic considerations of anticoagulant medication

86%
Miklosz J., Kalaska B., Mogielnicki A.
Journal of Physiology and Pharmacology
|
2018
|
tom 69
|
nr 4
4
Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik
Content available

Direct factor Xa inhibitor in the prevention of thromboembolism

72%
Meretskyi V., Meretska I., Pertsovych V.
Health Problems of Civilization
|
2018
|
tom 12
|
nr 4
Venous thromboembolism is the third most common cause of vascular death after myocardial infarction and stroke, and is associated with considerable morbidity and premature mortality. The incidence of the most serious consequence of venous thromboembolism, fatal pulmonary embolism, ranges from 0.01% to 5% among hospitalised medical patients with multiple risk factors, and is currently considered the commonest avoidable cause of hospital death. Rivaroxaban is a small-molecule factor Xa inhibitor that belongs to a new class of direct oral anticoagulant agents that directly inhibit single enzymes in the coagulation pathway. Rivaroxaban has many advantages over vitamin K antagonists and unfractionated heparin and may become an alternative to traditional anticoagulant agents in patients at risk for thromboembolism. Moreover, antidotes exist and are in the progress of development, both specific and non-specific, for the treatment of overdose or side effects, including bleeding.
5
Content available remote

Plasma fibrin clots of pulmonary embolism patients present increased amounts of factor XIII and alpha2-antiplasmin at 3 months’ anticoagulation since the acute phase

72%
Zabczyk M., Natorska J., Bagoly Z., Sarkady F., Barath B., Katona E., Bryk A., Zettl K., Wisniewski J. R., Undas A.
Journal of Physiology and Pharmacology
|
2020
|
tom 71
|
nr 4
6

Procoagulants and anticoagulants in fetal blood. A literature survey

72%
Uszynski M., Uszynski W., Szymanski M.
Folia Histochemica et Cytobiologica
|
2009
|
tom 47
|
nr 4
7

The influence of unfractionated and low-molecular weight heparins on the properties of human umbilical vein endothelial cells [HUVEC]

72%
Gasowska K., Naumnik B., Klejna K., Mysliwiec M.
Folia Histochemica et Cytobiologica
|
2009
|
tom 47
|
nr 1
17-23
8

Lysophosphatidylcholines: bioactive lipids generated during storage of blood components

72%
Maslanka K., Smolenska-Sym G., Michur H., Wrobel A., Lachert E., Brojer E.
Archivum Immunologiae et Therapiae Experimentalis
|
2012
|
tom 60
|
nr 1
9
Content available remote

Antithrombotic medications and their impact on fibrin clot structure and function

72%
Undas A., Zabczyk M.
Journal of Physiology and Pharmacology
|
2018
|
tom 69
|
nr 4
10

Contradictory functions of sulfatide in the blood coagulation system as coagulant and anticoagulant

72%
Kyogashima M., Onaya J., Hara A., Taketomi T.
Acta Biochimica Polonica
|
1998
|
tom 45
|
nr 2
Sulfatide (galactosylceramide I3 -sulfate) has been reported to activate blood coagulation factor XII (Hageman factor), which suggests that it exhibits coagulant activity (Fujikama et al., 1980 Biochemistry 19, 1322-1330) However, sulfatide administered into animals as a bolus shot without subsequent thrombus formation, prolonged conventional clotting times and bleeding time (Hara et al., 1996 Glycoconjugate J. 13, 187-194). These findings suggest that it may exhibit anticoagulant rather than coagulant activity. Following this suggestion we found in vitro that binding of sulfatide to fibrinogen resulted in disturbance of fibrin formation. To examine a possible pharmacological effect of sulfatide on blood coagulation in vivo we continuously infused sulfatide into rats through plastic cannulae and found formation of giant thrombi around the tips of the cannulae. These data suggest that sulfatide may exhibit contradictory functions in the blood coagulation system.
11
Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik
Content available

Experimental studies on the anticoagulant and antithrombotic effects of sodium and calcium pentosan polysulphate

72%
Giedrojc J., Radziwon P., Klimiuk M., Bielawiec M., Breddin H. K., Kloczko J.
Journal of Physiology and Pharmacology
|
1999
|
tom 50
|
nr 1
12

The effect of prophylactic doses of nadroparin and therapeutic doses of betamethasone on skin flap survival in rats

58%
Bielecki M., Karpik M., Skowronski J.
Folia Histochemica et Cytobiologica
|
2009
|
tom 47
|
nr 4
13

Cloning and expression of a new recombinant thrombolytic and antithrombotic agent - a staphylokinase variant

58%
Kowalski M., Brown G., Bieniasz M., Oszajca K., Chabielska E., Pietras T., Szemraj Z., Makandjou-Ola E., Bartkowiak J., Szemraj J.
Acta Biochimica Polonica
|
2009
|
tom 56
|
nr 1
41-53
 To develop a more potent antithrombin agent with thrombolytic and antiplatelet properties, a new staphylokinase (SAK) variant was constructed. The kringle 2 domain (K2) of tissue type-plasminogen activator (t-PA) containing a fibrin-specific binding site (i), the RGD sequence (Arg-Gly-Asp) for the prevention of platelet aggregation (ii) and the antithrombotic agent - hirulog (iii) was assembled to the C-terminal part of recombinant staphylokinase (r-SAK). cDNA for the hybrid protein SAK-RGD-K2-Hirul was cloned into Pichia pastoris pPIC9K yeast expression vector. The introduction of K2 t-PA, the RGD sequence and hirulog into the C-terminus of r-SAK did not alter the staphylokinase activity. We observed a higher clot lysis potency of SAK-RGD-K2-Hirul as evidenced by a faster and more profound lysis of 125I-labeled human fibrin clots. The potency of thrombin inhibition by the hirulog C-terminal part of the recombinant fusion protein was almost identical to that of r-Hir alone. These results suggest that the SAK-RGD-K2-Hirul construct can be a more potent and faster-acting thrombolytic agent with better antithrombin and antiplatelet properties compared to r-SAK and SAK-RGD-K2-Hir.
14
Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik
Content available

Effectiveness of difenacoum and brodifacoum against common vole (Microtus arvalis), mouse (Mus musculus v. Alba) and rabbit (Oryctolagus cuniculus) in the laboratory tests

58%
Romankow-Zmudowska A.
Prace Naukowe Instytutu Ochrony Roślin
|
1983
|
tom 25
|
nr 1
15

A comparative study of the protein C system in mother's blood, cord blood and amniotic fluid

58%
Uszynski M., Uszynski W., Zekanowska E., Kuczynski J., Szymanski M.
Folia Histochemica et Cytobiologica
|
2010
|
tom 48
|
nr 2
262-266
16

Interakcje witaminy K z pozywieniem i lekami

51%
Pasko P., Zachwieja Z.
Bromatologia i Chemia Toksykologiczna
|
2009
|
tom 42
|
nr 3
1036-1040
17

Investigation of interaction of human platelet membrane components with anticoagulant drugs abciximab and eptifibatide

51%
Gorodkiewicz E., Sankiewicz A., Figaszewski Z.
Folia Histochemica et Cytobiologica
|
2010
|
tom 48
|
nr 4
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.